Combination Antithrombotic Therapy with Antiplatelet Agents and Anticoagulants for Patients with Atherosclerotic Heart Disease

Journal of Invasive Cardiology

Volumn 16, Issue 5, 2004, Pages 271-278

  Arjomand, Heidar ^a   Cohen, Marc ^b   Ezekowitz, Michael D ^a  

^a HAHNEMANN UNIVERSITY HOSPITAL   (United States)

^b NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Antithrombotic therapy; Aspirin; Coronary artery disease; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; ORBOFIBAN; PLACEBO; SIBRAFIBAN; THROMBIN; THROMBIN INHIBITOR; TICLOPIDINE; WARFARIN; XEMILOFIBAN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CLINICAL RESEARCH; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG UTILIZATION; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART LEFT VENTRICLE ANEURYSM; HEART LEFT VENTRICLE FAILURE; HEART REINFARCTION; HIGH RISK PATIENT; HUMAN; INTERNATIONAL STANDARD UNIT; LOW DRUG DOSE; MEDLINE; MORTALITY; OUTCOMES RESEARCH; PARAMETER; PATIENT COMPLIANCE; PRIMARY PREVENTION; REVIEW; SECONDARY PREVENTION; STROKE; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; ANTICOAGULANTS; ASPIRIN; CEREBROVASCULAR ACCIDENT; CORONARY ARTERIOSCLEROSIS; DRUG THERAPY, COMBINATION; HEMORRHAGE; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS; THROMBOLYTIC THERAPY; WARFARIN;

EID: 2442622561     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Caims JA, Theroux P, Lewis HD Jr., et al. Antithrombotic agents in coronary artery disease. Chest 2001;119:228S-252S.
2. Brouwer MA, Verheugt FWA. Oral anticoagulation for acute coronary syndromes. Circulation 2002;105:1270-1274.
3. Peto R, Gray R, Collins R, et al. Randomized trial of daily aspirin in British male doctors. Br Med J 1988;296:313-316.
4. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing physicians' health study. N Engl J Med 1989;321:129-135.
5. Hansson L, Zanchetti AZ, Carruthers SG, et al., for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of hypertension optimal treatment (HOT) trial. Lancet 1998;351:1755-1762.
6. Collaborative group of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk A randomized trial in general practice. Lancet 2001;357:89-95.
7. Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: Randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. Lancet 1998;351:233-241.
8. Antithrombotic Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. Br Med J 2002;324:71-86.
9. CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;348:1329-1339.
10. Cohen M, Adams PC, McBride R, et al. Prospective comparison of patient characteristics and outcome on non-prior aspirin users versus aspirin users with unstable angina or non-Q wave myocardial infarction treated with combination antithrombotic therapy. J Thromb Thrombolysis 1997;4:275-280.
11. Antman EM, Cohen M, Bernink PJLM, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000;284:835-842.
12. Lancaster GI, Lancaster CJ, Radley D, et al. Prior aspirin use in unstable angina predisposes to higher risk: The aspirin paradox. Int J Cardiol 2001;80:201-207.
13. Eikelboom JW, Hirsh J, Wietz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-1655.
14. Chalmers TC, Matta RJ, Smith H Jr., et al. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. N Engl J Med 1977;297:1091-1096.
15. Smith P, Amesen H, Holme I. The effect of warfirin on mortality and reinfarction after myocardial infarcition. N Engl J Med 1990;323:147-152.
16. ASPECT Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994;343:499-503.
17. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomized double-blind trial of fixed-dose warfarin with aspirin after myocardial infarction. Lancet 1997;350:389-396.
18. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153-162.
19. Fiore LD, Ezekowitz MD, Brophy MT, et al., for the Combination Hemotherapy and Mortality Prevention (CHAMP) Study Group. Department of Veteran Affairs Cooperative Studies Program clinical trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction. Primary results of the CHAMP study. Circulation 2002;105:557-563.
20. Cohen M, Adams PC, Parry G, et al., and the Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Combination antithrombotic therapy in unstable rest angina and non-Q wave infarction in nonprior aspirin users. Primary endpoints analysis from the ATACS trial. Circulation 1994;89:81-88.
21. Anand SS, Yusuf S, Pogue J, et al., for the OASIS Pilot Study Investigators. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q wave myocardial infarction. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Pilot Study Results. Circulation 1998;98:1064-1070.
22. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. Effect of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. J Am Coll Cardiol 2001;37:475-484.
23. Williams MJA, Morison IM, Parker JH, et al. Progression of the culprit lesion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: Preliminary study. J Am Coll Cardiol 1997;30:364-369.
24. Verheugt FWA. The Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis-2 (APRICOT-2) Trial. Presented at 22nd European Congress of Cardiology; August 2000; Amsterdam, The Netherlands.
25. Van Ea RF, Jonker JCJ, Verheugt FWA, et al. Aspirin and coumadin after acute coronary syndromes (The ASPECT-2 study): A randomized trial. Lancet 2002;360:109-113.
26. Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin or both after myocardial infarction. N Engl J Med 2002;347:969-974.
27. Huynh T, Theroux P, Bogaty P, et al. Aspirin, warfarin of the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation 2001;103:3069-3074.
28. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: A meta-analysis. JAMA 1999;282:2058-2067.
29. Adams PC, Cohen M, Chesebro JH, et al. Thrombosis and embolism from cardiac chambers and infected valves. J Am Coll Cardiol 1986;6:76B-87B.
30. Ezekowitz MD, Wilson DA, Smith EO, et al. Comparison of indium-111 platelet scintigraphy and two-dimensional echocardiography in the diagnosis of left ventricular thrombi. N Engl J Med 1982;306:1509-1513.
31. Meltzer RS, Visser CA, Fuster V. Intracardiac thrombi and systemic embolization. Ann Intern Med 1986;104:689-698.
32. Bertrand ME, Rupprecht HJ, Urban P, et al., for the CLASSICS Investigators. The clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624-629.
33. Cutlip DE, Baim, DS, Ho KKL, et al. Stent thrombosis in the modern era. A pooled analysis of multicenter coronary stent clinical trials. Circulation 2001;103:1967-1971.
34. Lapeyre AC III, Steele PM, Kazmaier FJ, et al. Systemic embolism in chronic left ventricular aneurysm: Incidence and the role of anticoagulation. J Am Coll Cadiol 1985;6:534-538.
35. Eldar M, Canetti M, Rotstein Z, et al. Significance of paroxysmal atrial fibrillation complicating acute myocardial infarction in the thrombolytic era. SPRINT and Thrombolytic Survey Groups. Circulation 1998;97:965-970.
36. Rathore SS, Berger AK, Weinfurt KP, et al. Acute myocardial infarction complicated by atrial fibrillation in the elderly. Circulation 2000;101;969-974.
37. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veteran, Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992;372:1406-1412.
38. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457.
39. Albers GW, Dalen JE, Laupacis A, et al. Antithrombotic: therapy in atrial fibrillation. Chest 2001;119:194S-206S.
40. Loh E, Sutton MS, Wun CC, et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 1997;336:251-257.
41. Nabavi DG, Arato S, Droste DW, et al. Microembolic load in asymptomatic patients with cardiac aneurysm, severe ventricular dysfunction, and atrial fibrillation: Clinical and hemorheological correlates. Cerebrovasc Dis 1998;8:214-221.
42. The WASH Study Steering Committee and Investigators. The WASH Study (Warfarin/Aspirin Study of Heart Failure): Rationale, design and endpoints. Eur J Heart Fail 1999;1:95-99.
43. Karalis DG, Chandrasekaran K, Victor MF, et al. Recognition and embolic potential of intraaortic atherosclerotic debris. J Am Coll Cadiol 1991;17:73-78.
44. Tunick PA, Rosenzweig BP, Katz ES, et al. High risk for vascular events in patients with protruding aortic atheromas: A prospective study. J Am Coll Cardiol 1994;23:1085-1090.
45. Amarenco P, Cohen A, Tzourio C, et al. Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med 1994;331:1474-1479.
46. Vaduganathan P, Ewton A, Naugueh SF, et al. Pathologic correlates of aortic plaques, thrombi and mobile "aortic debris" imaged in vivo with transesophageal echocardiography. J Am Coll Cadiol 1997;30:357-363.
47. Dressler FA, Craig WR, Castello R, et al. Mobile aortic atheroma and systemic emboli: Efficacy of anticoagulation and influence of plaque morphology on recurrent stroke. J Am Coll Cardiol 1998;31:134-138.
48. Tunick PA, Kronzon I. Atheromas of the thoracic aortal: Clinical and therapeutic update. J Am Coll Cardiol 2000;55:545-554.
49. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann Intern Med 1998;128:639-647.
50. Ferrari E, Vidal R, Chevallier T, et al. Atherosclerosis of the thoracic aorta and aortic debris as a marker of poor prognosis. Benefits of oral anticoagulants. J Am Coll Cadiol 1999;33:1317-1322.
51. Fazio GP, Redberg RF, Winslow T, et al. Transesophageal echocardiographically detected atherosclerotic aortic plaque is a marker for coronary artery disease. J Am Coll Cardiol 1993;21:144-150.
52. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndrome without ST-segment elevation. N Engl J Med 2001;345:494-502
53. Gaspoz JM, Coxson PG, Goldman PA. et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary preveation of coronary heart disease. N Engl J Med 2002;346:1800-1806.
54. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty: A randomized double-blind trial. Ann Intern Med2002;137:648-655.
55. Petersen P, Grind M, Adler J, for the SPORTIF II Investigators. Ximelagaitian versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation; SPORTIF II: A dose-guiding, tolerability and safety study. J Am Coll Cardiol 2003;41:1445-1451.
56. Petersen P, on behalf of the SPORTIF II and IV Investigators. A long-term follow-up of ximelagatran as an oral anticoagulant for the prevention of stroke and systemic embolism inpatients with atrial fibrillation (Abstr). Blood 2001;98:706a.
57. Olsson SB and the Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): A randomized controlled trial. Lancet 2003;362:1691-1698.
58. Halperin JL, for the SPORTIF V Investigators. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation. Presented at American Heart Association Annual Scientific Session, November 2003, Orlando, Florida.
59. Wallentin L, Wilcox RG, Weaver WD, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: The ESTEEM randomized controlled. Lancet 2003;362:789-797.
60. Wallentin, on the behalf of the ESTEEM Investigators. Presented at American Heart Association Annual Scientific Session, November 2003, Orlando, Florida.
61. Chew DP, Bhatt DL, Sapp S, et al. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists. A meta-analysis of phase III multicenter randomized trials. Circulation 2001;103:201-206.
62. Mehta SR, Yusuf S, Peters RJ, et al., for the Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE Study. Lancet 2001;358:527-533.